Literature DB >> 19475018

Phosphorescence-Fluorescence ratio imaging for monitoring the oxygen status during photodynamic therapy.

H Sterenborg, J de Wolf, M Koning, B Kruijt, A van den Heuvel, D Robinson.   

Abstract

The effectiveness of photodynamic therapy is strongly dependent on the availabilty of oxygen. In the present paper we show that the ratio between photosensitiser phosphorescence and fluorescence is a parameter that can be used to monitor the competition between singlet oxygen production and other processes quenching the photosensitiser triplet state. We present a theoretical basis for the validity of this approach and a series of in vitro imaging experiments.

Entities:  

Year:  2004        PMID: 19475018     DOI: 10.1364/opex.12.001873

Source DB:  PubMed          Journal:  Opt Express        ISSN: 1094-4087            Impact factor:   3.894


  5 in total

1.  Insights into photodynamic therapy dosimetry: simultaneous singlet oxygen luminescence and photosensitizer photobleaching measurements.

Authors:  Mark T Jarvi; Michael S Patterson; Brian C Wilson
Journal:  Biophys J       Date:  2012-02-07       Impact factor: 4.033

Review 2.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Laser speckle imaging of dynamic changes in flow during photodynamic therapy.

Authors:  B Kruijt; H S de Bruijn; A van der Ploeg-van den Heuvel; H J C M Sterenborg; D J Robinson
Journal:  Lasers Med Sci       Date:  2006-10-13       Impact factor: 3.161

4.  Singlet Oxygen In Vivo: It Is All about Intensity.

Authors:  Steffen Hackbarth; Rayhanul Islam; Vladimír Šubr; Tomáš Etrych; Jun Fang
Journal:  J Pers Med       Date:  2022-05-28

5.  Choline PET for monitoring early tumor response to photodynamic therapy.

Authors:  Baowei Fei; Hesheng Wang; Chunying Wu; Song-mao Chiu
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.